Cynata Therapeutics Ltd - Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19
Cynata Therapeutics Ltd (ASX:CYP)

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19

Document   View Announcement

Highlights

What's happened?

Cynata Therapeutics Ltd (ASX:CYP "Cynata") has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19.

What are the key highlights?

  1. Compromised lung function, which can ultimately progress to acute respiratory distress syndrome (ARDS), is a major complication in COVID-19 patients.
  2. This trial will build on Cynata’s strong pre-clinical study results in ARDS, sepsis and cytokine release syndrome, all of which are common hallmarks of severe COVID-19 cases.
  3. The MEND trial is an open-label, randomised controlled clinical trial to investigate early efficacy of Cymerus MSCs.
  4. The MEND Trial is to be conducted at centres in New South Wales in collaboration with the Cerebral Palsy Alliance Research Institute and investigators from the COVID-19 Stem Cell Treatment (CSCT) Group.

CEO's Summary

Dr. Ross Macdonald

“The ethics approval of this proposed clinical trial is a major milestone for Cynata and our proprietary Cymerus MSC technology. Our substantial pre-clinical database in relevant disease models, together with the urgent need for more effective treatments for critically ill patients with COVID-19, allowed us to accelerate planning and rapidly achieve ethics committee approval. We are pleased to be able to move so quickly to further investigate the potential benefits our MSCs could have to treat patients in dire need during this global pandemic. This trial forms part of a broader clinical development strategy for our Cymerus MSC product to be trialled in COVID-19 patients in other countries. Our decision to focus on this new clinical development area is a logical and prudent step based on the current global environment and Cynata’s solid pre-clinical foundations in respiratory and related diseases.”

Dr. Ross Macdonald
CEO, Cynata Therapeutics Ltd
Question   Ask Dr. Ross Macdonald a question...

Download Announcement

View this announcement as well as our full profile on the company.
Document   View Announcement
View CYP's Full Profile Arrow Forward

How do I invest?

Considering investing in Cynata Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CYP

    On your online investment platform search for the stock ticker code ASX:CYP to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Trade for $9.50 Arrow Forward
Up